Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

[1]  M. Calasanz,et al.  Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression , 2015, Leukemia.

[2]  G. Mufti,et al.  High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.

[3]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[4]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[5]  P. Campbell,et al.  TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee , 2014 .

[6]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[7]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[8]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Campbell,et al.  Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.

[10]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[11]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[12]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[13]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[14]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Mufti,et al.  Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome , 2013, Haematologica.

[16]  G. Mufti,et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.

[17]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[18]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[19]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[20]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[21]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[22]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[24]  F. Passamonti,et al.  Clinical relevance of JAK2 (V617F) mutant allele burden , 2009, Haematologica.

[25]  B. Ko,et al.  RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.

[26]  M. Taniwaki,et al.  Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome , 2003, Leukemia & lymphoma.

[27]  M. Taniwaki,et al.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.

[28]  H. Kaneko,et al.  TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.

[29]  R. Berger,et al.  Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.